stockrowAlign Technology, Inc.
ALGN Healthcare Medical Instruments & Supplies
Align Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 0.90% from fiscal 2024.
- Revenue
- +1.92%
- EPS
- +143.9%
- Free cash flow
- +8.26%
Quarter to September 2026, against a year earlier
Follow ALGN
Alert me
Align Technology, Inc. (ALGN) EPS (diluted)
Align Technology, Inc.'s EPS (diluted) for fiscal 2025 was $5.65, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $6.87. Over the past ten years it has ranged from $1.77 (fiscal 2015) to $22.41 (fiscal 2020); the current reading is higher than 73% of that period. Align Technology, Inc. ranks 4th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $5.65 | 0.53% |
| FY2024 | $5.62 | (3.27%) |
| FY2023 | $5.81 | 26.03% |
| FY2022 | $4.61 | (52.43%) |
| FY2021 | $9.69 | (56.76%) |
| FY2020 | $22.41 | 305.24% |
| FY2019 | $5.53 | 12.40% |
| FY2018 | $4.92 | 73.85% |
| FY2017 | $2.83 | 21.46% |
| FY2016 | $2.33 | 31.64% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.90 | 25.93% |
| Jun 2026 | $1.51 | (3.82%) |
| Mar 2026 | $1.57 | (16.93%) |
| Dec 2025 | $1.89 | 142.31% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALGN Align Technology, Inc. | $6.87 |
| ATR AptarGroup, Inc. compare | $4.12 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| SOLV Solventum Corporation compare | $0.89 |
| AVTR Avantor, Inc. compare | $0.50 |
| RGEN Repligen Corporation compare | −$0.21 |
| BLCO Bausch + Lomb Corporation compare | −$0.30 |
| BAX Baxter International Inc. compare | −$1.41 |
| TFX Teleflex Incorporated compare | −$23.29 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ALGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement